Ihor Atabiekov

Dr. Ihor Atabiekov

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MCMichal Ciebiera
Michal Ciebiera
Mohamed AliMohamed Ali
Mohamed Ali
LPLillian Prince
Lillian Prince
TJTia Jackson-Bey
Tia Jackson-Bey
IAIhor Atabiekov
Ihor Atabiekov
Ayman A. Al-HendyAyman A. Al-Hendy
Ayman A. Al-Hendy
Uterine fibroids (UFs) remain a significant health issue for many women, with a disproportionate impact on women of color, likely due to both genetic and environmental factors. The prevalence of UFs is estimated to be approximately 70% depending on population. UF-derived clinical symptoms include pelvic pain, excessive uterine bleeding, gastrointestinal and voiding problems, as well as impaired fertility. Nowadays numerous methods of UF treatment are available—from conservative treatment to invasive surgeries. Selecting an appropriate treatment option should be individualized and adjusted to the patient's expectations as much as possible. So far, the mainstay of treatment is surgery, but their negative impact of future fertility is clear. On the other hand, emerging new pharmaceutical options have significant adverse effects like liver function impairment, hot flashes, bone density loss, endometrial changes, and inability to attempt conception during treatment. Several natural compounds are found to help treat UFs and relieve their symptoms. In this review we summarize all the current available data about natural compounds that may be beneficial for patients with UFs, especially those who want to preserve their future fertility or have treatment while actively pursuing conception. Vitamin D, epigallocatechin gallate, berberine, curcumin, and others are being used as alternative UF treatments. Moreover, we propose the concept of using combined therapies of natural compounds on their own or combined with hormonal agents to manage UFs. There is a strong need for more human clinical trials involving these compounds before promoting widespread usage.

1 October 2018 in Matrix Biology
Verified
Journal Article
Closed access
DLDaria Lizneva
Daria Lizneva
TYTony Yuen
Tony Yuen
LSLi Sun
Li Sun
SKSe-Min Kim
Se-Min Kim
IAIhor Atabiekov
Ihor Atabiekov
MZMone Zaidi
Mone Zaidi

1 November 2018 in Biomedicines
Verified
Journal Article
Open access
PDF file
IAIhor Atabiekov
Ihor Atabiekov
EHElie Hobeika
Elie Hobeika
USUjalla Sheikh
Ujalla Sheikh
AAAbdeljabar El Andaloussi
Abdeljabar El Andaloussi
Ayman A. Al-HendyAyman A. Al-Hendy
Ayman A. Al-Hendy
Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before the age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g.; anticancer treatment, genetic disorders, and enzymatic defects) could be identified. Although hormone-replacement therapy, the principal therapeutic approach for POI, helps alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, an effective approach to manage patients with POI is highly warranted. Several mechanisms associated with POI have been identified, including the lack of function of the follicle-stimulating hormone (FSH) receptor, alterations in apoptosis control, mutations in Sal-like 4 genes, and thymulin or basonuclin-1 deficiency. The above mentioned may be good targets for gene therapy in order to correct defects leading to POI. The goal of this review is to summarize current experiences on POI studies that employed gene therapy, and to discuss possible future directions in this field.

1 January 2018
Verified
Book Chapter
Closed access
DLDaria Lizneva
Daria Lizneva
IAIhor Atabiekov
Ihor Atabiekov
RARicardo Azziz
Ricardo Azziz

12 September 2018 in Preprints.org
Verified
Preprint
Open access
IAIhor Atabiekov
Ihor Atabiekov
EHElie Hobieka
Elie Hobieka
USUjalla Sheikh
Ujalla Sheikh
AAAbdeljabar El Andaloussi
Abdeljabar El Andaloussi
AAAyman Al-Hendy
Ayman Al-Hendy
Premature ovarian insufficiency (POI) is a highly prevalent disorder, characterized by the development of menopause before age of 40. Most cases are idiopathic; however, in some women the cause of this condition (e.g. anticancer treatment, genetic disorders, and enzymatic defects) may be identified. Although hormone replacement therapy, the principal therapeutic approach for POI, helps to alleviate the related symptoms, this does not effectively solve the issue of fertility. Assisted reproductive techniques also lack efficacy in these women. Thus, the effective approach to manage the patients with POI is highly warranted. Several mechanisms, associated with POI, have been identified, including lack of FSH receptor functioning, alterations in the apoptosis control, mutations in Sal-like 4 genes, thymulin or basonuclin-1 deficiency etc. The above-mentioned may be good targets for gene therapy in order to correct defects, leading to POI. The goal of this review is to summarize the current experience on the POI studies, that employed gene therapy, and to discuss the possible future directions in this field.

1 January 2021 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
IAIhor Atabiekov
Ihor Atabiekov
AGA.V. Golovin
A.V. Golovin
IFI.V. Fesak
I.V. Fesak
KKK.N. Kazimov
K.N. Kazimov
IDI.N. Dzhansyz
I.N. Dzhansyz